These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 30741673)
1. Transgenerational Interaction of Alzheimer's Disease with Schizophrenia through Amyloid Evolvability. Takamatsu Y; Ho G; Waragai M; Wada R; Sugama S; Takenouchi T; Masliah E; Hashimoto M J Alzheimers Dis; 2019; 68(2):473-481. PubMed ID: 30741673 [TBL] [Abstract][Full Text] [Related]
2. Understanding Creutzfeldt-Jackob disease from a viewpoint of amyloidogenic evolvability. Hashimoto M; Ho G; Takamatsu Y; Wada R; Sugama S; Waragai M; Masliah E; Takenouchi T Prion; 2020 Dec; 14(1):1-8. PubMed ID: 32375593 [TBL] [Abstract][Full Text] [Related]
3. Possible Role of Amyloid Cross-Seeding in Evolvability and Neurodegenerative Disease. Hashimoto M; Ho G; Takamatsu Y; Wada R; Sugama S; Takenouchi T; Waragai M; Masliah E J Parkinsons Dis; 2019; 9(4):793-802. PubMed ID: 31524179 [TBL] [Abstract][Full Text] [Related]
4. Possible Role of the Polyglutamine Elongation in Evolution of Amyloid-Related Evolvability. Hashimoto M; Ho G; Takamatsu Y; Wada R; Sugama S; Takenouchi T; Masliah E; Waragai M J Huntingtons Dis; 2018; 7(4):297-307. PubMed ID: 30372687 [TBL] [Abstract][Full Text] [Related]
5. Evolvability and Neurodegenerative Disease: Antagonistic Pleiotropy Phenomena Derived from Amyloid Aggregates. Hashimoto M; Ho G; Takamatsu Y; Shimizu Y; Sugama S; Takenouchi T; Waragai M; Masliah E J Parkinsons Dis; 2018; 8(3):405-408. PubMed ID: 30010144 [TBL] [Abstract][Full Text] [Related]
6. Connecting Alzheimer's Disease With Diabetes Mellitus Through Amyloidogenic Evolvability. Ho G; Takamatsu Y; Wada R; Sugama S; Waragai M; Takenouchi T; Masliah E; Hashimoto M Front Aging Neurosci; 2020; 12():576192. PubMed ID: 33192467 [TBL] [Abstract][Full Text] [Related]
7. Evolvability of Amyloidogenic Proteins in Human Brain. Hashimoto M; Ho G; Sugama S; Takamatsu Y; Shimizu Y; Takenouchi T; Waragai M; Masliah E J Alzheimers Dis; 2018; 62(1):73-83. PubMed ID: 29439348 [TBL] [Abstract][Full Text] [Related]
8. Adiponectin Paradox in Alzheimer's Disease; Relevance to Amyloidogenic Evolvability? Waragai M; Ho G; Takamatsu Y; Wada R; Sugama S; Takenouchi T; Masliah E; Hashimoto M Front Endocrinol (Lausanne); 2020; 11():108. PubMed ID: 32194507 [TBL] [Abstract][Full Text] [Related]
9. Motor and Nonmotor Symptoms of Parkinson's Disease: Antagonistic Pleiotropy Phenomena Derived from Takamatsu Y; Fujita M; Ho GJ; Wada R; Sugama S; Takenouchi T; Waragai M; Masliah E; Hashimoto M Parkinsons Dis; 2018; 2018():5789424. PubMed ID: 30595837 [TBL] [Abstract][Full Text] [Related]
10. Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy. Wei J; Ho G; Masliah E; Hashimoto M Prion; 2023 Dec; 17(1):29-34. PubMed ID: 36785484 [TBL] [Abstract][Full Text] [Related]
11. Possible Role of Activin in the Adiponectin Paradox-Induced Progress of Alzheimer's Disease. Hashimoto M; Ho G; Sugama S; Takenouchi T; Waragai M; Sugino H; Inoue S; Masliah E J Alzheimers Dis; 2021; 81(2):451-458. PubMed ID: 33814453 [TBL] [Abstract][Full Text] [Related]
12. Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review. Chung JK; Nakajima S; Plitman E; Iwata Y; Uy D; Gerretsen P; Caravaggio F; Chakravarty MM; Graff-Guerrero A Am J Geriatr Psychiatry; 2016 Oct; 24(10):923-39. PubMed ID: 27526990 [TBL] [Abstract][Full Text] [Related]
13. Network-based analysis on the genes and their interactions reveals link between schizophrenia and Alzheimer's disease. Guo P; Meng C; Zhang S; Cai Y; Huang J; Shu J; Wang J; Cai C Neuropharmacology; 2024 Feb; 244():109802. PubMed ID: 38043643 [TBL] [Abstract][Full Text] [Related]
14. Adiponectin paradox as a therapeutic target of the cancer evolvability in aging. Takamatsu Y; Ho G; Wada R; Inoue S; Hashimoto M Neoplasia; 2021 Jan; 23(1):112-117. PubMed ID: 33310207 [TBL] [Abstract][Full Text] [Related]
15. Adiponectin Paradox as a Therapeutic Target in Alzheimer's Disease. Waragai M; Ho G; Takamatsu Y; Wada R; Sugama S; Takenouchi T; Masliah E; Hashimoto M J Alzheimers Dis; 2020; 76(4):1249-1253. PubMed ID: 32623396 [TBL] [Abstract][Full Text] [Related]
17. Analysis of mRNA and Protein Levels of Di Maio A; De Rosa A; Pelucchi S; Garofalo M; Marciano B; Nuzzo T; Gardoni F; Isidori AM; Di Luca M; Errico F; De Bartolomeis A; Marcello E; Usiello A Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163460 [TBL] [Abstract][Full Text] [Related]
18. Alzheimer's disease (AD) therapeutics - 2: Beyond amyloid - Re-defining AD and its causality to discover effective therapeutics. Mullane K; Williams M Biochem Pharmacol; 2018 Dec; 158():376-401. PubMed ID: 30273552 [TBL] [Abstract][Full Text] [Related]
19. Reconsideration of Alzheimer's Disease Therapy from a Viewpoint of Amyloidogenic Evolvability. Ho G; Choo PC; Waragai M; Inoue S; Masliah E; Hashimoto M J Alzheimers Dis Rep; 2022; 6(1):207-210. PubMed ID: 35591950 [TBL] [Abstract][Full Text] [Related]
20. Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer's disease. Wakabayashi T; Yamaguchi K; Matsui K; Sano T; Kubota T; Hashimoto T; Mano A; Yamada K; Matsuo Y; Kubota N; Kadowaki T; Iwatsubo T Mol Neurodegener; 2019 Apr; 14(1):15. PubMed ID: 30975165 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]